Retrospective chart review reveals feasible tolerability of subcutaneous bolus pantoprazole in hospice patients, suggesting an alternative route when swallowing is impaired.
OBJECTIVE: To investigate the use, feasibility and tolerability of bolus subcutaneous injection of pantoprazole in the specialist palliative care hospice inpatient setting. METHOD: A retrospective review of the electronic records and paper administration charts of the first 10 patients who received a slow bolus subcutaneous injection of pantoprazole in a hospice inpatient unit. RESULTS: The most common indications for a proton pump inhibitor were gastro-esophageal reflux disease and gastroprotection. Loss of swallow in the last days of life was the most common reason for the subcutaneous route. 80% of patients tolerated bolus subcutaneous pantoprazole and may have received clinical benefit. Two patients developed skin irritation at the subcutaneous injection site. CONCLUSION: Bolus subcutaneous pantoprazole is a potential alternative treatment when a proton pump inhibitor is indicated, and the oral route is not available or effective. There is a risk of skin irritation requiring careful monitoring. Controlled research is needed.
No takes yet. Share an insight, caveat, or question.
Naylor et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: